The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Open accessAbstract
Summary Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting α-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation. Small molecule inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clinical and clinical development. In this review, we provide an overview of mutant IDH-targeted therapy and discuss a number of important recent pre-clinical studies using models of IDH-mutant solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
TET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
Choi, C., Ganji, S. K., DeBerardinis, R. J., Hatanpaa, K. J., Rakheja, D., Kovacs, Z., Yang, X.-L., Mashimo, T., Raisanen, J. M., Marin-Valencia, I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2682 · Cited by 839
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Koh, K. P., Yabuuchi, A., Rao, S., Huang, Y., Cunniff, K., Nardone, J., Laiho, A., Tahiliani, M., Sommer, C. A., Mostoslavsky, G., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.01.008 · Cited by 776
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
Self-citationA vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 555
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Cairns, R. A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J.-P., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 509
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1034 · Cited by 471 · cited 3×
“It is critical to note that the collective results from pre-clinical and clinical studies of IDHmutant leukemia suggest that mutant IDH1/2 inhibitors are efficacious due to a reduction of D2HG levels, which removes a barrier to myeloid differentiation and thus promotes differentiation of mutant IDH-expressing blast ce…”
BackgroundMethodMutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornella, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K.-L., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 458
Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456
Andronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate
Tyrakis, P. A., Palazon, A., Macias, D., Lee, K. L., Phan, A. T., Veliça, P., You, J., Chia, G. S., Sim, J., Doedens, A., et al. (2016) · Nature · doi:10.1038/nature20165 · Cited by 433
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
Kohanbash, G., Carrera, D. A., Shrivastav, S., Ahn, B. J., Jahan, N., Mazor, T., Chheda, Z. S., Downey, K. M., Watchmaker, P. B., Beppler, C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90644 · Cited by 410
Mutant IDH1 regulates the tumor-associated immune system in gliomas
Amankulor, N. M., Kim, Y., Arora, S., Kargl, J., Szulzewsky, F., Hanke, M., Margineantu, D. H., Rao, A., Bolouri, H., Delrow, J., et al. (2017) · Genes & Development · doi:10.1101/gad.294991.116 · Cited by 405
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Amatangelo, M. D., Quek, L., Shih, A., Stein, E. M., Roshal, M., David, M. D., Marteyn, B., Farnoud, N. R., de Botton, S., Bernard, O. A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779447 · Cited by 359
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., DiNardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. (2017) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 350
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Sasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282
Self-citationCorrelation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöhrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 254
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
Fu, X., Chin, R. M., Vergnes, L., Hwang, H., Deng, G., Xing, Y., Pai, M. Y., Li, S., Ta, L., Fazlollahi, F., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.009 · Cited by 235
Dang, L., & Su, S.-S. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044732 · Cited by 204
DiNardo, C. D., Propert, K. J., Loren, A. W., Paietta, E., Sun, Z., Levine, R. L., Straley, K. S., Yen, K., Patel, J. P., Agresta, S., et al. (2013) · Blood · doi:10.1182/blood-2013-03-493197 · Cited by 198
An in vivo patient-derived model of endogenous IDH1-mutant glioma
Luchman, H. A., Stechishin, O. D., Dang, N. H., Blough, M. D., Chesnelong, C., Kelly, J. J., Nguyen, S. A., Chan, J. A., Weljie, A. M., Cairncross, J. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor207 · Cited by 198
Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
Carbonneau, M., M. Gagné, L., Lalonde, M.-E., Germain, M.-A., Motorina, A., Guiot, M.-C., Secco, B., Vincent, E. E., Tumber, A., Hulea, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms12700 · Cited by 180
Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas
Elkhaled, A., Jalbert, L. E., Phillips, J. J., Yoshihara, H. A. I., Parvataneni, R., Srinivasan, R., Bourne, G., Berger, M. S., Chang, S. M., Cha, S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002796 · Cited by 180
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J.-T., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 176
Self-citationPan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Pusch, S., Krausert, S., Fischer, V., Balss, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.-C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1677-y · Cited by 173
Kernytsky, A., Wang, F., Hansen, E., Schalm, S., Straley, K., Gliser, C., Yang, H., Travins, J., Murray, S., Dorsch, M., et al. (2015) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 172
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E., Chi, A., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 171
Zhang, X., Rao, A., Sette, P., Deibert, C., Pomerantz, A., Kim, W. J., Kohanbash, G., Chang, Y., Park, Y., Engh, J. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now061 · Cited by 171
Enasidenib: First Global Approval
Kim, E. S. (2017) · Drugs · doi:10.1007/s40265-017-0813-2 · Cited by 171
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 168
Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 167
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 160
Kawaguchi, T., Sonoda, Y., Shibahara, I., Saito, R., Kanamori, M., Kumabe, T., & Tominaga, T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2201-2 · Cited by 158
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Chiang, S., Weigelt, B., Wen, H., Pareja, F. G., Raghavendra, A., Martelotto, L. G., Burke, K. A., Basili, T., Li, A., Geyer, F. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0298 · Cited by 145
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
Mazor, T., Chesnelong, C., Pankov, A., Jalbert, L. E., Hong, C., Hayes, J. L., Smirnov, I. V., Marshall, R. E., de Souza, C. F., Shen, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708914114 · Cited by 143
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 132
Self-citationIsocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
Gaal, J., Burnichon, N., Korpershoek, E., Roncelin, I., Bertherat, J. Y., Plouin, P., de Krijger, R. R., Gimenez‐Roqueplo, A., & Dinjens, W. N. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2170 · Cited by 131
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 128
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Pellegatta, S., Valletta, L., Corbetta, C., Patanè, M., Zucca, I., Sirtori, F. R., Bruzzone, M. G., Fogliatto, G., Isacchi, A., Pollo, B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0180-0 · Cited by 127
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
Emir, U. E., Larkin, S. J., de Pennington, N., Voets, N., Plaha, P., Stacey, R. J., Al-Qahtani, K., McCullagh, J., Schofield, C. J., Clare, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0934 · Cited by 125
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Karpel‐Massler, G., Ishida, C. T., Bianchetti, E., Zhang, Y., Shu, C., Tsujiuchi, T., Banu, M. A., Garcia, F., Roth, K. A., Bruce, J. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00984-9 · Cited by 121
Hominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma
Chen, R., Nishimura, M. C., Kharbanda, S., Peale, F., Deng, Y., Daemen, A., Forrest, W. F., Kwong, M., Hedehus, M., Hatzivassiliou, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409653111 · Cited by 117
Multiple NADPH-producing pathways control glutathione (GSH) content in retina
Winkler, B. S., Desantis, N. M., & Solomon, F. (1986) · Experimental Eye Research · doi:10.1016/s0014-4835(86)80013-6 · Cited by 107
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Johannessen, T.-C. A., Mukherjee, J., Viswanath, P., Ohba, S., Ronen, S. M., Bjerkvig, R., & Pieper, R. O. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0141 · Cited by 107
Birendra, K. C., & Dinardo, C. D. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.04.006 · Cited by 99
Reitman, Z. J., Duncan, C. G., Poteet, E. C., Winters, A., Yan, L., Gooden, D. M., Spasojević, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 97
Self-citationLeather, T., Jenkinson, M. D., Das, K., & Poptani, H. (2017) · Metabolites · doi:10.3390/metabo7020029 · Cited by 68
Pusch, S., Sahm, F., Meyer, J., Mittelbronn, M. G. A., Hartmann, C. J., & von Deimling, A. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01127.x · Cited by 61
Lopez, G. Y., Reitman, Z. J., Solomon, D. A., Waldman, T. A., Bigner, D. D., McLendon, R. E., Rosenberg, S. A., Samuels, Y., & Yan, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.125 · Cited by 59
Self-citationKim, J., Kim, K. Y., Jang, H., Yoshida, T., Tsuchiya, K., Nitta, K., Park, J., Bonventre, J. V., & Park, K. M. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90566.2008 · Cited by 51
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit
Kopinja, J. E., Sevilla, R. S., Levitan, D. J., Dai, D. L., Vanko, A., Spooner, E., Ware, C., Forget, R., Hu, K., Kral, A. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14065-w · Cited by 51
Waitkus, M. S., Pirozzi, C. J., Moure, C. J., Diplas, B. H., Hansen, L. J., Carpenter, A. B., Yang, R. R., Wang, Z., Ingram, B. O., Karoly, E. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1352 · Cited by 48
Self-citationMutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression
Pirozzi, C. J., Carpenter, A. B., Waitkus, M. S., Wang, C. Y., Zhu, H., Hansen, L. J., Chen, L. H., Greer, P. K., Feng, J., Wang, Y., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0485 · Cited by 44
Self-citationMellinghoff, I. K., Touat, M., Maher, E. A., de la Fuente, M. I., Cloughesy, T. F., Holdhoff, M., Cote, G. M., Burris, H. A., Jankú, F., Huang, R., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox168.037 · Cited by 35
Whitehall, V., Dumenil, T. D., McKeone, D., Bond, C., Bettington, M. L., Buttenshaw, R. L., Bowdler, L. M., Montgomery, G. W., Wockner, L. F., & Leggett, B. (2014) · Epigenetics · doi:10.4161/15592294.2014.971624 · Cited by 28
The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Chen, J., Yang, J., & Cao, P. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666160609085520 · Cited by 28
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Navigating the DNA methylation landscape of cancer
Nishiyama, A., & Nakanishi, M. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.05.002 · Cited by 972
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
Ju, H.-Q., Lin, J.-F., Tian, T., Xie, D., & Xu, R.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00326-0 · Cited by 581
Metadata
- Authors
- Waitkus, M. S., Diplas, B. H., & Yan, H.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 34
- Issue
- 2
- Pages
- 186-195
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2803357178
- Cited by
- 335
- References
- 88
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.